Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors

Trial Profile

A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Concizumab (Primary) ; Eptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Proof of concept; Therapeutic Use
  • Acronyms explorer™4
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 14 Dec 2021 Results (N=61) from phase 2 trials explorer4 (NCT03196284) and explorer5 (NCT03196297) describing surgeries and diagnostic procedures presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 14 Dec 2021 Results of an exploratory pooled analyses (of explorer4 (NCT03196284) and explorer5 (NCT03196297) phase 2 trials) assessing changes in HRQoL after long-term concizumab treatment presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 08 Dec 2020 Results from the extension part assessing safety and longer term efficacy presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top